Adenosine Deaminase-Severe Combined Immunodeficiency Market Outlook Signals Expansion To $8.1 Billion Through 2030

The adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market is positioned for significant growth in the upcoming years, driven by advances in therapy options and expanding healthcare resources. This market's evolution reflects ongoing innovations in treatment approaches and increased attention to rare genetic disorders, which collectively pave the way for enhanced patient outcomes and broader access to care.

Projected Market Growth and Size of the Adenosine Deaminase-Severe Combined Immunodeficiency Market
Forecasts suggest the ADA-SCID market will reach a valuation of $8.11 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4%. This expansion is largely fueled by breakthroughs in autologous stem cell therapies, greater availability of enzyme replacement therapies, proliferation of specialized healthcare facilities, higher rates of pediatric diagnosis, and increased funding dedicated to rare genetic conditions. Key trends shaping this market include the growing use of enzyme replacement therapies, advancements in gene therapy development and accessibility, a rise in stem cell transplantation procedures, expansion of pediatric treatment programs specific to ADA-SCID, and a stronger emphasis on supportive care and patient monitoring techniques.

The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.94 billion in 2025 to $6.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to limited awareness of ada-scid, low availability of gene therapy solutions, reliance on supportive care treatments, lack of specialized treatment centers, high prevalence of treatment delays.

Download a free sample of the adenosine deaminase-severe combined immunodeficiency market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21085&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Primary Companies Influencing the Adenosine Deaminase-Severe Combined Immunodeficiency Market
The ADA-SCID market features a range of influential players such as GlaxoSmithKline plc, Chiesi Farmaceutici S.p.A., Orchard Therapeutics PLC, Rocket Pharmaceuticals, Novartis AG, Bluebird Bio, Spark Therapeutics, Leadiant Biosciences, Sigma-Tau Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, Pfizer Inc, Sanofi, Bristol-Myers Squibb, Roche Holding AG, Johnson & Johnson, AbbVie Inc, Gilead Sciences, CSL Limited, and Bayer AG.

A notable development occurred in January 2024 when Kyowa Kirin Co., Ltd., a pharmaceutical company based in Japan, acquired Orchard Therapeutics plc., a UK-based gene therapy specialist. This acquisition was intended to reinforce Kyowa Kirin's commitment to innovating treatments for rare and complex diseases by leveraging Orchard's expertise in gene therapy platforms.

View the full adenosine deaminase-severe combined immunodeficiency market report:
https://www.thebusinessresearchcompany.com/report/adenosine-deaminase-severe-combined-immunodeficiency-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends in the Global Adenosine Deaminase-Severe Combined Immunodeficiency Market
Leading organizations in the ADA-SCID treatment field are increasingly focusing on producing gene therapies internally, aiming to improve patient access, lower costs, and maintain a steady supply chain. This strategy involves manufacturing autologous hematopoietic stem cells genetically modified with a functional ADA gene within their own facilities, thus minimizing reliance on external suppliers.

For example, in February 2025, Italy's Fondazione Telethon, a nonprofit biomedical research group, submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for etuvetidigene autotemcel. This gene therapy, initially created for ADA-SCID, is now also being tested for treating Wiskott-Aldrich Syndrome. The treatment involves a single dose of autologous CD34+ stem and progenitor cells modified with a lentiviral vector carrying the functional gene, demonstrating promising safety and effectiveness in clinical trials.

Breakdown of Segments Within the Adenosine Deaminase-Severe Combined Immunodeficiency Market
This report categorizes the ADA-SCID market into several key segments:

1) Treatment Type:
- Enzyme Replacement Therapy (ERT)
- Gene Therapy
- Stem Cell Transplantation
- Supportive Care Treatments

2) Route of Administration:
- Intravenous
- Subcutaneous

3) End-User:
- Hospitals
- Specialty Clinics

Further subsegment details include:
- Enzyme Replacement Therapy (ERT): Pegylated Adenosine Deaminase, Non-Pegylated Adenosine Deaminase
- Gene Therapy: Autologous Stem Cell-Based Gene Therapy, Viral Vector-Mediated Gene Therapy
- Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant, Umbilical Cord Blood Transplant
- Supportive Care Treatments: Antimicrobial Therapy, Immune System Support

This segmentation helps to clearly define the diverse treatment approaches, administration methods, and healthcare settings involved in managing ADA-SCID.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.